Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 12/20 | 0.47 |
| ▸ | PRCP | P42785 | 1/20 | 0.45 |
| ▸ | TACR1 | P25103 | 12/20 | 0.42 |
| ▸ | TACR2 | P21452 | 4/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | CCR3 | P51677 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.37 |
| ▸ | NPY2R | P49146 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL921671 | 0.87 | TACR3 (0.52) | TACR3PRCPTACR1TACR2CCR5 | |
| SCHEMBL295621 | 0.84 | TACR3 (0.59) | TACR3TACR1TACR2HRH1CCR3 | |
| SCHEMBL298316 | 0.83 | TACR3 (0.46) | TACR3TACR1TACR2HRH1CCR3 | |
| SCHEMBL296751 | 0.83 | TACR3 (0.44) | TACR3TACR1TACR2HRH1CCR3 | |
| SCHEMBL296719 | 0.81 | TACR1 (0.56) | TACR3PRCPTACR1TACR2 | |
| SCHEMBL296888 | 0.81 | TACR3 (0.45) | TACR3TACR1TACR2HRH1CCR3 | |
| SCHEMBL3858335 | 0.79 | TACR3 (0.53) | TACR3PRCPTACR1TACR2CCR5 | |
| SCHEMBL297808 | 0.79 | KCNH2 (0.41) | TACR3TACR1TACR2HRH1CCR3 | |
| SCHEMBL296624 | 0.77 | KCNH2 (0.40) | TACR3TACR1TACR2HRH1CCR3 | |
| SCHEMBL296833 | 0.77 | TACR3 (0.66) | TACR3PRCPTACR1TACR2CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200982-B1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-20110021565-A1 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | KNUST HENNER | 2011-01-27 | — | — | US | disclosed |
| US-20090076081-A1 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076081-A1 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | DRD2, DRD3, OPRL1 | TACR3 95/4885PRCP 3287/4885TACR1 26/4885 |
| US-20110021565-A1 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | DRD2, DRD3, OPRL1 | TACR3 95/4885PRCP 3287/4885TACR1 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.